News Headlines Article

Study: Bone drug lowers breast cancer risk 38% in high-risk women
USA Today

A common osteoporosis drug, raloxifene, reduces breast cancer risk by 38% in women at high risk for the disease, without causing the serious side effects of similar drugs, a new study shows. That suggests more high-risk women should consider taking raloxifene, also known as Evista, says Victor Vogel, main author of the study presented Monday at the American Association for Cancer Research meeting in Washington.